Loading
Breast medical oncologist and Deputy CEO for clinical operations at the National Cancer Centre Singapore, an international leader in triple-negative breast cancer trials.
Rebecca Dent is Deputy Chief Executive Officer for clinical operations at the National Cancer Centre Singapore and a senior consultant in medical oncology. Her research focuses on triple-negative and early breast cancer, and she has been a lead investigator on international phase 3 trials of immunotherapy and targeted agents in breast cancer. She chairs and contributes to international breast cancer guideline and consensus groups.
The first-line overall survival result that made an antibody-drug conjugate the standard for PD-L1-negative or immunotherapy-ineligible metastatic triple-negative disease, and the reason the sequencing question (which TROP2 drug first, what after it) is now urgent.
LOTUS and PAKT together made the PI3K/AKT/PTEN-altered subgroup the target population for AKT inhibitors in TNBC; the phase 3 IPATunity130 later failed to confirm it, which is why no AKT inhibitor is approved here.
Explains why triple-negative trials can use three-year event-free survival, why follow-up is front-loaded, and why survivors past five years are told their risk has largely passed.
Shares Breast cancer research and treatment, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
Shares HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.